HC Wainwright Issues Positive Outlook for ORIC Earnings

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – HC Wainwright lifted their Q1 2026 earnings estimates for Oric Pharmaceuticals in a research report issued on Tuesday, February 24th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.31) per share for the quarter, up from their previous forecast of ($0.37). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.28) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04.

ORIC has been the subject of a number of other research reports. Citigroup increased their target price on Oric Pharmaceuticals from $16.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Thursday, January 22nd. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Tuesday. Wells Fargo & Company boosted their target price on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oric Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $20.20.

Oric Pharmaceuticals Price Performance

NASDAQ:ORIC opened at $13.40 on Thursday. The business’s 50-day moving average is $10.17 and its two-hundred day moving average is $10.96. The firm has a market capitalization of $1.34 billion, a PE ratio of -8.82 and a beta of 1.35. Oric Pharmaceuticals has a 12 month low of $3.90 and a 12 month high of $14.93.

Hedge Funds Weigh In On Oric Pharmaceuticals

Large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after buying an additional 977 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Oric Pharmaceuticals by 3.9% in the 4th quarter. California State Teachers Retirement System now owns 33,959 shares of the company’s stock valued at $278,000 after acquiring an additional 1,270 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Oric Pharmaceuticals by 2.9% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 49,000 shares of the company’s stock valued at $497,000 after acquiring an additional 1,358 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Oric Pharmaceuticals by 35.9% during the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 5,194 shares of the company’s stock valued at $53,000 after acquiring an additional 1,372 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Oric Pharmaceuticals by 12.9% in the third quarter. ProShare Advisors LLC now owns 13,383 shares of the company’s stock worth $161,000 after purchasing an additional 1,527 shares during the period. Institutional investors own 95.05% of the company’s stock.

Insider Activity

In other news, CFO Dominic Piscitelli sold 10,720 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company’s stock, valued at approximately $617,420.88. This trade represents a 13.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pratik S. Multani sold 10,720 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the sale, the insider owned 68,149 shares of the company’s stock, valued at approximately $617,429.94. This trade represents a 13.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 54,814 shares of company stock worth $496,615. 6.82% of the stock is currently owned by insiders.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.